Inclusion Criteria:  Over 18 years. Patients treated with ustekinumab in induction and maintenance phase. They must agree to participate in the clinical study, having previously signed the informed consent.  Exclusion Criteria:  Any patient who does not meet the inclusion criteria previously described and / or who refuses to participate in the study.